LQAI yields 1.11% · JNJ yields 2.13%● Live data
📍 JNJ pulled ahead of the other in Year 6
Combined, LQAI + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of LQAI + JNJ for your $10,000?
LQAI launches through a partnership between the AI research division of LG, the South Korean company that makes TVs and home appliances, and Qraft Tech. The fund employs a proprietary artificial intelligence (AI) system for selection while maintaining oversight from the fund's adviser. The AI identifies patterns and creates a balanced exposure to the five factors influencing the US market: quality (profitability), size (market capitalization), value (price-to-book ratio), momentum, and volatility. The fund evaluates the impact of each factor on companies and selects the top 100 stocks based on the average distribution of each stock's relative superiority in price appreciation. These stocks are also poised to outperform their peers in the upcoming month. Due to the monthly updates to the database, LQAI is expected to trade securities frequently, potentially resulting in a high portfolio turnover. The Fund restricts single company weightings to 10% and securities with over 5% weighting to 40% of assets in aggregate. Although investments are heavily reliant on QRAFT AI recommendations, the adviser maintains the final decision-making authority in investment choices.
Full LQAI Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.